此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

除颤和可靠性先导评估 (LEADR)

2026年10月13日 更新者:Medtronic Cardiac Rhythm and Heart Failure

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.

The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.

研究概览

详细说明

The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (332 subjects enrolled).

研究类型

介入性

注册 (实际的)

1007

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Chengdu、中国
        • LEADR & LEADR LBBAP: West China Hospital of Sichuan University
    • Shanxi
      • Taiyuan、Shanxi、中国、030000
        • LEADR: Shanxi Cardiovascular Hospital
      • Copenhagen、丹麦、2100
        • LEADR: Rigshospitalet
    • Alberta
      • Calgary、Alberta、加拿大、T2N 4N1
        • LEADR: University of Calgary
    • Ontario
      • Newmarket、Ontario、加拿大、L3Y8C3
        • LEADR: Southlake Regional Health Centre
    • Quebec
      • Québec、Quebec、加拿大、G1V 4G5
        • LEADR & LEADR LBBAP: Institut Universitaire de Cardiologie et de Pneumologie de Quebec
      • Belgrade、塞尔维亚
        • LEADR: Klinicki Centar Srbije Pejsmejker centar
    • Mitterweg
      • Krems、Mitterweg、奥地利、3500
        • LEADR: Universitätsklinikum Krems
    • Bielefeld
      • Bielefeld、Bielefeld、德国、33604
        • LEADR: Klinikum Bielefeld Kardiologie
      • Bergamo、意大利、24127
        • LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
    • Singapore
      • Singapore、Singapore、新加坡
        • LEADR: Ng Teng Fong General Hospital
    • Fukuoka
      • Kitakyushu、Fukuoka、日本、802-8555
        • LEADR & LEADR LBBAP: Kokura Memorial Hospital
    • Osaka
      • Suita、Osaka、日本、564-8565
        • LEADR & LEADR LBBAP: National Cerebral and Cardiovascular Center
    • Tokyo
      • Shinjuku-Ku、Tokyo、日本、162-8666
        • LEADR: Tokyo Women's Medical University Hospital
    • Antwerp
      • Edegem、Antwerp、比利时、2650
        • LEADR LBBAP: Universitair Ziekenhuis Antwerpen
      • La Tronche、法国、38700
        • LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord
      • Montpellier、法国、34960
        • LEADR LBBAP: OC Santé - Clinique du Millénaire
      • Rouen、法国、76031
        • LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle
      • Krakow、波兰
        • LEADR LBBAP: Szpital Uniwersytecki w Krakowie
      • Garran、澳大利亚、2605
        • LEADR &LEADR LBBAP: Canberra Hospital
    • Queensland
      • Chermside、Queensland、澳大利亚、4032
        • LEADR & LEADR LBBAP: The Prince Charles Hospital
    • South Australia
      • Ashford、South Australia、澳大利亚、8032
        • LEADR: Ashford Hospital
      • Norwood、South Australia、澳大利亚、5000
        • LEADR & LEADR LBBAP: Royal Adelaide
    • Alabama
      • Huntsville、Alabama、美国、35801
        • LEADR: Heart Center Research
    • California
      • Torrance、California、美国、90505
        • LEADR LBBAP: Torrance Memorial Medical Center
    • Connecticut
      • Hartford、Connecticut、美国、06106
        • LEADR: Hartford Hospital
    • Florida
      • Tampa、Florida、美国、33606
        • LEADR: University of South Florida
    • Minnesota
      • Minneapolis、Minnesota、美国、55407
        • LEADR & LEADR LBBAP: Minneapolis Heart Institute Foundation
    • Missouri
      • Kansas City、Missouri、美国、64111
        • LEADR: Saint Luke's Mid America Heart Institute
      • St Louis、Missouri、美国、63110
        • LEADR: Washington University School of Medicine
    • New Jersey
      • Voorhees Township、New Jersey、美国、08034
        • LEADR: Lourdes Cardiology Services
    • New Mexico
      • Albuquerque、New Mexico、美国、87108
        • LEADR: Presbyterian Heart Group
    • New York
      • Bay Shore、New York、美国、11030
        • LEADR & LEADR LBBAP: South Shore University Hospital/Northwell Health
    • Ohio
      • Cincinnati、Ohio、美国、45202
        • LEADR: TriHealth Hatton Research Institute
      • Cincinnati、Ohio、美国、45219
        • LEADR LBBAP: The Christ Hospital
      • Cleveland、Ohio、美国、44195
        • LEADR: Cleveland Clinic
      • Columbus、Ohio、美国、43210
        • LEADR LBBAP: The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18103
        • LEADR: Lehigh Valley Hospital - Cedar Crest
      • Philadelphia、Pennsylvania、美国、19104
        • LEADR: Hospital of the University of Pennsylvania
      • Wilkes-Barre、Pennsylvania、美国、18711
        • LEADR LBBAP: Geisinger Wyoming Valley Medical Center
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • LEADR& LEADR LBBAP: Vanderbilt University medical Center
    • Texas
      • Austin、Texas、美国、78705
        • LEADR: Texas Cardiac Arrhythmia Research Foundation
      • Fort Worth、Texas、美国、76104
        • LEADR: Texas Health Fort Worth Hospital
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • LEADR & LEADR LBBAP: University of Virginia Medical Center
      • Richmond、Virginia、美国、23298
        • LEADR & LEADR LBBAP: Virginia Commonwealth University Health System
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53215
        • LEADR LBBAP: Aurora St. Luke's Hospital
      • London、英国、W12 0HS
        • LEADR & LEADR LBBAP: Imperial College Healthcare NHS Trust - Hammersmith Hospital
    • Limburg
      • Maastricht、Limburg、荷兰
        • LEADR LBBAP: Maastricht Universitair Medisch Centrum
      • Carnaxide、葡萄牙、2790-134
        • LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology
      • L'Hospitalet de Llobregat、西班牙
        • LEADR: Hospital Universitari Bellvitge
      • Valencia、西班牙、46026
        • LEADR: Hospital Universitario y Politécnico La Fe
    • Granada
      • Granada、Granada、西班牙、18014
        • LEADR LBBAP: Hospital Universitario Virgen de las Nieves
      • Hong Kong、香港
        • LEADR & LEADR LBBAP: Queen Mary Hospital
      • Lai Chi Kok、香港、999077
        • LEADR: Princess Margaret Hospital
      • Kuala Lumpur、马来西亚、50400
        • LEADR & LEADR LBBAP: Institut Jantung Negara - National Heart Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

LEADR Inclusion Criteria:

  • Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:

    • de novo Medtronic CRT-D system implant
    • de novo Medtronic ICD system implant (single or dual chamber)
  • Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)

  • Subject is willing to undergo implant defibrillation testing if requested.

  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.

LEADR Exclusion Criteria:

  • Subject is unwilling or unable to personally provide Informed Consent.

  • Subject has contraindications for standard RV transvenous lead placement (e.g., mechanical right heart valve).

  • Subject is contraindicated for ≤1 mg dexamethasone acetate.

  • Subject has a life expectancy of less than 12 months

  • For subject undergoing defibrillation testing the following medical conditions exclude them:

    • Pre-existing or suspected pneumothorax during implant
    • Current intracardiac left atrial or left ventricular (LV) thrombus
    • Severe aortic stenosis
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Unstable angina
    • Ejection Fraction less than 25%
    • Recent stroke or transient ischemic attack (within the last 6 months)
    • Known inadequate external defibrillation
    • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.

  • Subject with any exclusion criteria as required by local law (e.g., age or other).

  • Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence

  • Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads

  • Subject with any evidence of active infection or undergoing treatment for an infection

  • Recent (or planned) cardiac surgery or stenting less than 1 month before implant

  • End stage renal disease

  • Subjects with NYHA IV classification

  • Subjects with a transplanted heart

  • Subjects with previously extracted leads

  • Subjects with Left Ventricular Assist Device

LEADR LBBAP Inclusion Criteria:

  • Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:

    a) De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)

  • Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.

  • Subject provides written authorization and/or consent per institution and geographical requirements.

  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up

  • Subject is willing to undergo implant defibrillation testing if requested

LEADR LBBAP Exclusion Criteria:

  • Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)

  • Subject is contraindicated for ≤1 mg dexamethasone acetate

  • Subject has a life expectancy of less than 12 months

  • For subject undergoing defibrillation testing the following medical conditions exclude them:

    • Pre-existing or suspected pneumothorax
    • Current intracardiac left atrial or LV thrombus
    • Severe aortic stenosis
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Unstable angina
    • Recent stroke or transient ischemic attack (within the last 6 months)
    • Known inadequate external defibrillation
    • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager

  • Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence

  • Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads

  • Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant

  • Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days

  • Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours

  • Subjects with end stage renal disease

  • Subjects with NYHA IV classification

  • Subjects with a transplanted heart or on the waiting list for a heart transplant

  • Subjects with previously extracted leads

  • Subjects with Left Ventricular Assist Device

  • Subjects that are vulnerable adults

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention/Treatment (LEADR)

Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing

Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

实验性的:Intervention/Treatment (LEADR LBBAP)

Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing

Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months
大体时间:Implant to 6 Months

Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.

Implant to 6 Months
LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
大体时间:Day 1

Defibrillation testing will be completed in a subset of subjects at implant.

Day 1
LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
大体时间:Day 1

Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.

Day 1
LEADR LBBAP: The Lead-related Major Complication Rate at 3-months
大体时间:Implant to 3 Months

Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.

Implant to 3 Months

次要结果测量

结果测量
措施说明
大体时间
LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead
大体时间:up to 18 months

Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.

up to 18 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:George Crossley, MD、Vanderbilt University (LEADR)
  • 首席研究员:Pugazhendhi Vijayaraman, MD、Geisinger Medical Center (LEADR LBBAP)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年6月21日

初级完成 (实际的)

2025年9月3日

研究完成 (实际的)

2025年11月6日

研究注册日期

首次提交

2021年4月21日

首先提交符合 QC 标准的

2021年4月26日

首次发布 (实际的)

2021年4月28日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年10月13日

最后验证

2025年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅